E-viri
Recenzirano
-
Poynard, Thierry; Calès, Paul; Pasta, Linda; Ideo, Gaetano; Pascal, Jean-Pierre; Pagliaro, Luigi; Lebrec, Didier
The New England journal of medicine, 05/1991, Letnik: 324, Številka: 22Journal Article
THE continuous administration of beta-adrenergic—antagonist drugs induces a sustained decrease in portal pressure in patients with cirrhosis. 1 2 3 4 As a result, these drugs have been used to prevent gastrointestinal bleeding, a leading cause of death in patients with portal hypertension. There are published reports of four randomized clinical trials of beta-adrenergic—antagonist drug treatment — two using propranolol 5 , 6 and two using nadolol 7 , 8 — to prevent a first episode of gastrointestinal bleeding due to portal hypertension in patients with cirrhosis. The percentages of patients who had no bleeding and the survival rates were dissimilar in these four trials. In two studies, the treatment . . .
